Keryx Biopharmaceuticals (NASDAQ:KERX) contracts experienced interesting call activity in the options market. There were 4.0 calls traded for each put contract yielding a 0.25 put/call ratio. Specifically, 4,011 put and 16,209 call contracts exchanged hands yesterday. On last trading day Keryx Biopharmaceuticals (NASDAQ:KERX) ended up 17.39%higher to close at $16.54 while trading in the range of $14.15 – $17.29. Its return on assets (ROA) is -59.80% while return on investment (ROI) is -103.70%.Keryx Biopharmaceuticals (NASDAQ:KERX) monthly performance is -1.55%.

China Biologic Products, Inc. (NASDAQ:CBPO), a leading fully integrated plasma-based biopharmaceutical company in China, on 19 march announced that the Company has received the Good Manufacturing Practice (“GMP”) certification from China Food and Drug Administration (“CFDA”) in respect of its plasma production facility at its Guizhou subsidiary. China Biologic Products Inc. (NASDAQ:CBPO) in last trading activity ended up at $35.04 with day range of $33.50 – $35.87. Company weekly performance is -2.67% while its quarterly performance stands at 19.55%.China Biologic Products Inc. (NASDAQ:CBPO) is -9.22% away from its 52 week high.

Fate Therapeutics Inc. (NASDAQ:FATE) recently issued its fourth quarter earnings, which more or less was in line with the consensus estimate. Fate Therapeutics Inc. (NASDAQ:FATE) belongs to Healthcare sector with market capitalization of 15.51 million and has 1.20% insider ownership. In last trading activity company’s stock closed at $12.28 while opening price was $11.25.

Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, will report financial results for the fourth quarter and full year ended December 31, 2013, after the market close on Thursday, March 27, 2014. On Wednesday shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) opened at $9.69 and closed at $10.06. This year Company’s Earnings per Share (EPS) growth is -2.19 and next year’s estimated EPS growth is -7.40%. Analysts mean target price for Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is $17.20.